Shyeilla V. Dhuria

2.1k citations

24 papers · 1.7k indexed · 1 hit paper · h-index 13

Pharmaceutical Science top 0.5%
Sensory Systems top 5%
Endocrine and Autonomic Systems top 5%
Neurology top 10%
Cellular and Molecular Neuroscience top 10%
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 10
Oncology
- HER2/EGFR in Cancer Research 5
- Cancer-related Molecular Pathways 3
Molecular Biology
- Cell death mechanisms and regulation 4
Cognitive Neuroscience
- Sleep and Wakefulness Research 3
Epidemiology
- Neuroendocrine Tumor Research Advances 2
Genetics
- Chronic Lymphocytic Leukemia Research 2
Experimental and Cognitive Psychology
- Sleep and related disorders 2

Co-authors: Leah R. Hanson William H. Frey Scott B. Cameron E. Claire Dees Jeffrey R. Infante Roger B. Cohen Anthony J. Olszanski Michelle C. Miller
Cited by: Pharmaceutical Science Sensory Systems Endocrine and Autonomic Systems
Journals: Journal of Clinical Oncology (6 papers)Cancer Research (3 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations: United States Spain Switzerland

In The Last Decade

Shyeilla V. Dhuria

24 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Shyeilla V. Dhuria

Since Specialization

Citations

This map shows the geographic impact of Shyeilla V. Dhuria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shyeilla V. Dhuria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shyeilla V. Dhuria more than expected).

Fields of papers citing papers by Shyeilla V. Dhuria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shyeilla V. Dhuria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shyeilla V. Dhuria. The network helps show where Shyeilla V. Dhuria may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Shyeilla V. Dhuria, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Shyeilla V. Dhuria Line = papers co-authored together Shyeilla V. Dhuria links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	AB0794 A PROSPECTIVE STUDY ON RENAL INVOLVEMENT IN INDIAN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS Annals of the Rheumatic Diseases ·Sumita Ghosh,Kaustubh Telang,Lokesh Kumar Sharma,GG Ekbote,Dhaval Tanna,Shyeilla V. Dhuria,V K Singal,Rajiva Gupta	2023	1
2	DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1/2 study Molecular Genetics and Metabolism ·Akhil Bhalla,Khishig Tsogtbaatar,Ritesh Ravi,Meng Fang,Sonnet S. Davis,Imanol Zubizarreta,Ajith Karunakara,Yuda Zhu,Elizabeth Sinclair,Dominique Jacquemet-Engelhart,Shyeilla V. Dhuria,Tony T. N. Hung,Matthew D. Troyer,Peter Chin,Jeff M. Harris,Anna I. Bakardjiev	2023	1
3	Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling Clinical Pharmacology & Therapeutics ·Tanay S. Samant,Felix Huth,Kenichi Umehara,Hilmar Schiller,Shyeilla V. Dhuria,Mohamed Elmeliegy,Michelle C. Miller,Abhijit Chakraborty,Tycho Heimbach,Handan He,Yan Ji	2020	25
4	No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects Clinical Pharmacology in Drug Development ·Taylor A. Choi,Allison Komirenko,Valerie Riddle,Aryun Kim,Shyeilla V. Dhuria	2019	6
5	Use of a secure mobile application to inform clinicians on adverse event management and drug-drug interactions for ribociclib: Experiences with CT scholar in ribociclib clinical trials. Journal of Clinical Oncology ·Tania Small,Najla Bugazia,Brigette Nezami,Michael Vinegra,Alberto Ocaña,Shyeilla V. Dhuria,Jaclyn Feeley,Lance Burroughs	2017	1
6	Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations Clinical Pharmacology & Therapeutics ·Tanay S. Samant,Shyeilla V. Dhuria,Yasong Lu,Marc Laisney,Shu Yang,Arnaud Grandeury,Martin Mueller‐Zsigmondy,Kenichi Umehara,Felix Huth,Michelle C. Miller,Caroline Germa,Mohamed Elmeliegy	2017	64
7	Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study The Breast ·Giuseppe Curigliano,P. Gómez Pardo,Funda Meric‐Bernstam,Pierfranco Conté,Martijn P. Lolkema,J. Thaddeus Beck,Aditya Bardia,Maria Martinez‐García,Frédérique Penault‐Llorca,Shyeilla V. Dhuria,Zhongwen Tang,Nadia Solovieff,Michelle C. Miller,Emmanuelle di Tomaso,Sara A. Hurvitz	2016	104
8	Food consumption and activity levels increase in rats following intranasal Hypocretin-1 Neuroscience Letters ·Shyeilla V. Dhuria,Jared M. Fine,Deborah Bingham,Aleta L. Svitak,Rachel B. Burns,Amanda M. Baillargeon,S. Scott Panter,Abdul N. Kazi,William H. Frey,Leah R. Hanson	2016	19
9	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. Journal of Clinical Oncology ·Peter A. Fasching,Guy Jérusalem,Xavier Pivot,Miguel Martín,Michelino De Laurentiis,Kimberly Blackwell,Francisco J. Esteva,Stephen Chia,Caroline Germa,Zhongwen Tang,Shyeilla V. Dhuria,Dennis J. Slamon	2016	13
10	Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis. Journal of Clinical Oncology ·Dejan Juric,Pamela N. Münster,Mario Campone,Roohi Ismail‐Khan,Laura García‐Estévez,Erika Hamilton,Carlos Becerra,Richard H. De Boer,Rina Hui,Anthony Gonçalvès,Yingbo Wang,Shyeilla V. Dhuria,Ghulam H. Kalimi,Karen Cristina Rodriguez Lorenc,Ingrid A. Mayer	2016	30
11	LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2 Annals of Oncology ·Yoon Sim Yap,L-M. Tseng,K. L. Blackwell,David Cameron,Serene S. Foo,Virote Sriuranpong,C-S. Huang,T-Y. Chao,T.-Y. Kim,S-C. Chen,K.H. Jung,K.S. Lee,J-H. Sohn,Jae Hyoung Kim,Ming‐Feng Hou,Yunah Han,Farida Souami,Shyeilla V. Dhuria,Marshall G. Miller,Sunil Verma	2016	7
12	Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7. Journal of Clinical Oncology ·Debu Tripathy,Aditya Bardia,Sara A. Hurvitz,Nadia Harbeck,Marco Colleoni,Fábio Franke,Louis W.C. Chow,Seock‐Ah Im,Zhimin Shao,John R. Keyserlingk,Lidia Mongay Soler,Melissa Horan,Shyeilla V. Dhuria,Gareth Hughes,Yen‐Shen Lu	2015	6
13	A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects. Journal of Clinical Oncology ·Shyeilla V. Dhuria,Ravi Siddani,Chelsea Marie Kosecki,Caroline Germa,Sabiha Mondal	2015	3
14	Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Jeffrey R. Infante,E. Claire Dees,Anthony J. Olszanski,Shyeilla V. Dhuria,Suman Sen,Scott B. Cameron,Roger B. Cohen	2014	166
15	Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects The Journal of Clinical Pharmacology ·Shyeilla V. Dhuria,Heidi J. Einolf,James B. Mangold,Suman Sen,Helen Gu,Lai Wang,Scott B. Cameron	2013	17
16	Abstract PD5-7: Phase Ib study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with weekly paclitaxel in patients with advanced solid tumors: Safety and efficacy results, including breast cancer cohort Cancer Research ·Rodrigo Dienstmann,Bárbara Adamo,Laura Vidal,EC Dees,Stephen Chia,EL Mayer,TS Baney,Shyeilla V. Dhuria,Sen Sk,D Papoutsakis,Scott B. Cameron,J. R. Infante	2013	1
17	Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer Cancer Research ·Jeffrey R. Infante,E. Claire Dees,Howard A. Burris,Leigh Zawel,Jason A. Sager,Claudina Stevenson,Kathryn Clarke,Shyeilla V. Dhuria,Dale Porter,Suman Sen,Erika A. Zannou,Sushil Sharma,Roger B. Cohen	2010	18
18	Intranasal delivery to the central nervous system: Mechanisms and experimental considerationsbreakdown → Journal of Pharmaceutical Sciences ·Shyeilla V. Dhuria,Leah R. Hanson,William H. Frey	2009	964
19	Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System Journal of Pharmacology and Experimental Therapeutics ·Shyeilla V. Dhuria,Leah R. Hanson,William H. Frey	2008	79
20	Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system Journal of Pharmaceutical Sciences ·Shyeilla V. Dhuria,Leah R. Hanson,William H. Frey	2008	98

About Shyeilla V. Dhuria

Shyeilla V. Dhuria is a scholar working on Oncology, Family Practice and Sensory Systems, having authored 24 papers that have together received 1.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (10 papers), HER2/EGFR in Cancer Research (5 papers), Cell death mechanisms and regulation (4 papers), Cancer-related Molecular Pathways (3 papers), Sleep and Wakefulness Research (3 papers), Neuroendocrine Tumor Research Advances (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Sleep and related disorders (2 papers). The work is most often cited by research in Pharmaceutical Science (507 citations), Sensory Systems (97 citations) and Endocrine and Autonomic Systems (118 citations). Shyeilla V. Dhuria has collaborated with scholars based in United States, Spain and Switzerland. Frequent co-authors include Leah R. Hanson, William H. Frey, Scott B. Cameron, E. Claire Dees, Jeffrey R. Infante, Roger B. Cohen, Anthony J. Olszanski, Michelle C. Miller, Kenichi Umehara and Mohamed Elmeliegy. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact